Proteon Therapeutics (PRTO) Stock Price, News & Analysis

Company Overview

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.

Key Stats

• Today's Range: $4.10 to $4.50
• 50-Day Range: $0.84 to $25.13
• 52-Week Range: $0.22 to $3.94
• Volume: 440,734 shs
• Average Volume: 1.11 million shs
• Market Capitalization: $95.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PRTO Stock Analysis - Frequently Asked Questions

How were Proteon Therapeutics' earnings last quarter?

Proteon Therapeutics Inc (NASDAQ:PRTO) posted its earnings results on Thursday, October, 31st. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.01.

What other stocks do shareholders of Proteon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Proteon Therapeutics investors own include Bristol-Myers Squibb (BMY), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), ImmunoGen (IMGN), Onconova Therapeutics (ONTX), Sierra Oncology (SRRA) and Tonix Pharmaceuticals (TNXP).

Company Calendar

• Last Earnings: 10/31/2019
• Today: 4/26/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:PRTO
• CIK: 1359931
• Web: www.proteontherapeutics.com
• Phone: 781-890-0102
• Fax: N/A
• Employees: 17
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-20,730,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -118.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.98
• Quick Ratio: 5.98

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.06) per share
• Price / Book: -72.00

Miscellaneous

• Outstanding Shares: 22,179,000
• Free Float: N/A
• Market Cap: $95.81 million
• Optionable: Not Optionable
• Beta: 0.60